Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.
about
Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series)DNA Damage and Pulmonary HypertensionDysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertensionThe Risk of Oxygen during Cardiac Surgery (ROCS) trial: study protocol for a randomized clinical trialBMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertensionExpression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis.Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular MetabolismEndothelial uncoupling protein 2 regulates mitophagy and pulmonary hypertension during intermittent hypoxiaOestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension.Mitochondrial dysfunction in the APP/PSEN1 mouse model of Alzheimer's disease and a novel protective role for ascorbate.Mitochondrial dysfunction and pulmonary hypertension: Cause, Effect or Both.Parabiotic model for differentiating local and systemic effects of continuous and intermittent hypoxia.A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies.BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series).
P2860
Q26772286-094151B4-AB74-4C19-830E-4718EF3F60F1Q27005594-4273863E-2F1B-4990-92FD-C805B0511863Q33738642-57A7548E-CF75-4D31-B898-3F5D63FB234AQ33837039-C3444964-8F6F-4122-82D1-9CD677253714Q35376926-6E5323BA-1EE3-43D2-B6B6-9B6D9A9EEE30Q36352101-A972B6B9-F2FC-4FF0-9C89-015FBD828DF5Q36421287-1B677AA4-6D75-4C38-851A-4516463B3A75Q36490033-FC87F5DD-4EBA-4542-8C7F-93302CD92F7AQ38642429-F4FF2F92-342C-4D33-AC46-E4EA9FA6B0DDQ38779774-9945E087-F00B-4104-93EB-06A481A174EBQ44360290-4DE500B4-2243-43E7-901F-14A28A8FA165Q46313170-A0B648BB-4B4B-4592-B2E6-EDEF4C0C3637Q47726007-819011F7-7813-4070-A9E8-CB07BD5F9113Q48017846-6B1DCE75-23B5-4C81-9649-58D33EF69113Q50455228-F643FC07-C365-4D16-B309-6C53F93D34DAQ55008475-D90F6EA6-69DF-41A1-B14E-AF843207EAA0
P2860
Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Hyperoxia synergizes with muta ...... y, and pulmonary hypertension.
@en
Hyperoxia synergizes with muta ...... y, and pulmonary hypertension.
@nl
type
label
Hyperoxia synergizes with muta ...... y, and pulmonary hypertension.
@en
Hyperoxia synergizes with muta ...... y, and pulmonary hypertension.
@nl
prefLabel
Hyperoxia synergizes with muta ...... y, and pulmonary hypertension.
@en
Hyperoxia synergizes with muta ...... y, and pulmonary hypertension.
@nl
P2093
P2860
P356
P1476
Hyperoxia synergizes with muta ...... ry, and pulmonary hypertension
@en
P2093
Anna R Hemnes
Christie J Kang
David H Wasserman
James D West
Joshua P Fessel
Linda J Robinson
Niki L Penner
Santhi Gladson
P2860
P304
P356
10.1165/RCMB.2012-0463OC
P577
2013-11-01T00:00:00Z